Compare FC & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FC | EDIT |
|---|---|---|
| Founded | 1983 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 193.2M | 202.1M |
| IPO Year | 1992 | 2016 |
| Metric | FC | EDIT |
|---|---|---|
| Price | $19.95 | $2.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $26.00 | $4.50 |
| AVG Volume (30 Days) | 151.4K | ★ 2.0M |
| Earning Date | 01-07-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $262,026,000.00 | $46,383,000.00 |
| Revenue This Year | $3.22 | N/A |
| Revenue Next Year | $2.21 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.04 | $0.91 |
| 52 Week High | $39.22 | $4.54 |
| Indicator | FC | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 60.70 | 45.17 |
| Support Level | $19.79 | $2.05 |
| Resistance Level | $21.46 | $2.43 |
| Average True Range (ATR) | 1.03 | 0.15 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 72.99 | 31.47 |
Franklin Covey Co is a company focused on organizational performance improvement. It focuses on providing time management and effectiveness training for individuals and corporations via online training as well as in-person workshops and events. The company provides training and consulting services in the areas of leadership, execution, productivity, trust, sales performance, customer loyalty, and educational improvement. It operates in the business segments of Direct Offices, Education division, and International Licensees. The company derives revenue from providing training and consulting services, and through the selling of books, audio media, and other related products. It has a business presence in the Australia, New Zealand, China, Japan, United Kingdom, Ireland, and Other countries.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.